These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18254036)

  • 1. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults.
    Greb A; Bohlius J; Schiefer D; Schwarzer G; Schulz H; Engert A
    Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD004024. PubMed ID: 18254036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis.
    Strehl J; Mey U; Glasmacher A; Djulbegovic B; Mayr C; Gorschlüter M; Ziske C; Schmidt-Wolf IG
    Haematologica; 2003 Nov; 88(11):1304-15. PubMed ID: 14607760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
    Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis.
    Greb A; Bohlius J; Trelle S; Schiefer D; De Souza CA; Gisselbrecht C; Intragumtornchai T; Kaiser U; Kluin-Nelemans HC; Martelli M; Milpied NJ; Santini G; Verdonck LF; Vitolo U; Schwarzer G; Engert A
    Cancer Treat Rev; 2007 Jun; 33(4):338-46. PubMed ID: 17400393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma.
    Fagnoni P; Milpied N; Limat S; Deconinck E; Nerich V; Foussard C; Colombat P; Harousseau JL; Woronoff-Lemsi MC;
    Pharmacoeconomics; 2009; 27(1):55-68. PubMed ID: 19178124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; Caron HN; van Dalen EC
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Prayoonwiwat W; Numbenjapon T; Assawametha N; O'Charoen R; Swasdikul D
    Clin Lymphoma; 2000 Dec; 1(3):219-25. PubMed ID: 11707834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.
    Kriegsmann K; Rieger M; Schwarzbich MA; Sitter S; Kriegsmann M; Bruckner T; Hensel M; Ho AD; Witzens-Harig M; Wuchter P
    Eur J Haematol; 2018 Jul; 101(1):12-20. PubMed ID: 29575332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
    Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
    Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.
    Farquhar C; Marjoribanks J; Basser R; Hetrick S; Lethaby A
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD003142. PubMed ID: 16034887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard chemotherapy is superior to high-dose chemotherapy with autologous stem cell transplantation on overall survival as the first-line therapy for patients with aggressive non-Hodgkin lymphoma: a meta-analysis.
    Wang J; Zhan P; Ouyang J; Chen B; Zhou R; Yang Y
    Med Oncol; 2011 Sep; 28(3):822-8. PubMed ID: 20373054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
    Monjanel H; Deconinck E; Perrodeau E; Gastinne T; Delwail V; Moreau A; François S; Berthou C; Gyan E; Milpied N;
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):935-40. PubMed ID: 21109011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.
    Peinemann F; Smith LA; Bartel C
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD008216. PubMed ID: 23925699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.